Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 60.96B |
| Revenue (ttm) | 10.60B |
| Net Income (ttm) | 3.41B |
| Shares Out | n/a |
| EPS (ttm) | 30.94 |
| PE Ratio | 17.90 |
| Forward PE | 16.65 |
| Dividend | 2.68 (0.34%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 270 |
| Average Volume | 430 |
| Open | 807.99 |
| Previous Close | 808.15 |
| Day's Range | 792.81 - 820.00 |
| 52-Week Range | 477.01 - 820.00 |
| Beta | n/a |
| RSI | 63.31 |
| Earnings Date | Jan 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News
Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ: REGN). And retail traders should know. We noticed this today when the positions showed up on p...
REGN Crosses Above Average Analyst Target
In recent trading, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $797.92, changing hands for $812.27/share. When a stock reac...
Regeneron Just Moved From Underperform To Buy - Here's Why
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment? ... Full story available on Benzinga.com
Regeneron Just Moved From Underperform To Buy - Here's Why
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment?
Regeneron (REGN) Upgraded to Buy by BofA Securities
Regeneron (REGN) Upgraded to Buy by BofA Securities
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline
BofA upgrades Regeneron to buy, boosting Eylea HD and Dupixent sales outlook plus pipeline catalysts. Read more here.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals (NASDAQ: REGN) has outperformed the market over the past 20 years by 12.83% on an annualized basis producing an average annual return of 21.62%. Currently, Regeneron Pharmac...
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Analyst Upgrade: Regeneron Pharmaceuticals (REGN) Rating Boosted to Buy | REGN Stock News
Analyst Upgrade: Regeneron Pharmaceuticals (REGN) Rating Boosted to Buy | REGN Stock News
Peering Into Regeneron Pharmaceuticals Inc's Recent Short Interest
Regeneron Pharmaceuticals Inc's (NYSE: REGN) short interest as a percent of float has fallen 12.97% since its last report. According to exchange reported data, there are now 2.74 million shares sold ...
REGN vs. ILMN: Which Stock Should Value Investors Buy Now?
REGN vs. ILMN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Witnessing An Insider Decision, George L Sing Exercises Options Valued At $2.32M At Regeneron Pharmaceuticals
In a new SEC filing on December 31, it was revealed that Sing, Board Member at Regeneron Pharmaceuticals (NASDAQ: REGN), executed a significant exercise of company stock options. What Happened: A For...
When Phase 3 Data Drops, What Determines A Sustained Rally Vs. A Fading Initial Pop
The biotech sector has always been a high-stakes game where a single clinical trial result can send shares soaring or crashing within hours. As 2025 draws to a close, several companies have demonstrat...
REGN Factor-Based Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strat...
Regeneron Pharmaceuticals's Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ: REGN). And retail traders should know. We noticed this today when the positions showed up on p...
Sanofi, Regeneron’s Dupixent approved in Japan for children with asthma
Sanofi And Regeneron's Dupixent Wins Japan Nod For Pediatric Asthma
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) yesterday announced that Japan's Ministry of Health, Labor and Welfare has approved Dupixent for children aged 6 to 11 years with se...
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo